Joshua Mali, MD, is a vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida.

Joshua Mali, MD

home

authors

joshua-mali-md

, a blog series featuring contributions from members of the ophthalmic community. These blogs are an opportunity for ophthalmic bloggers to engage with readers with about a topic that is top of mind, whether it is practice management, experiences with patients, the industry, medicine in general, or healthcare reform. The series continues with this blog by 

, a vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, FL. The views expressed in these blogs are those of their respective contributors and do not represent the views of 

Ophthalmology Times® or MJH Life Sciences.

Watch Dr. Mali's interview on what ophthalmologists should expect from the new year.

It is that exciting time of the year when I once again reveal my top 5 predictions in ophthalmology for 2021.



1. While COVID-19 will continue to dominate the headlines in 2021, the human spirit and innovation will ultimately achieve victory and prevail.

will likely continue to be the dominant story well into 2021. This virus has impacted every part of our society. 

However, I strongly believe in humanity’s ability to defeat this challenge through our unity in spirit and incredible ingenuity in innovation. It has been amazing to see the speed, efficiency, and potency of the worldwide efforts in clinical research and the pharmaceutical industry to fight and crush this virus. It is really an industry-wide team effort, with companies both big and small joining the battle. 

For example, as of this writing, pharmaceutical giant Pfizer distributing its 

vaccine with a massive distribution plan unseen in our country’s history. While possibly equally as impressive, small biotech company — Sorrento Therapeutics — has rapidly developed a tremendous pipeline of promising COVID-19 antibody treatments, vaccine candidates, and diagnostic tests that could hold the key to next generational management and a potential cure for this disease. 

Our unity as a society with unshakeable will and determination is what will win the battle against 

, and this takes the top spot in my predictions for 2021.




2. The competition battle lines will be drawn in 2021 for ocular therapeutics in the most common eye disease markets

 did impact the vast majority of our society, surprisingly. clinical research in ophthalmology did not stop. In fact, it continues to grow at a record pace with incredible amounts of data to analyze and interpret for clinical application in ophthalmology. 

With that as a backdrop, 2021 will see product launches and regulatory approvals for ocular treatments in all the major disease states in ophthalmology: dry eye, glaucoma, cataract/intraocular lens implants, and macular degeneration. 

We have never seen such innovation in multiple common ocular disease states simultaneously until now. 

A few potentially impactful players in 2021 to keep your eye on are Genentech and Kala Pharmaceuticals. Genentech delivers significant optimism with two exciting products: its Port Delivery System with ranibizumab (PDS) for exudative age-related macular degeneration (AMD) to provide a revolutionary sustained drug delivery system; and faricimab, the first bispecific antibody designed for intraocular use that can simultaneously bind and neutralize Ang-2 and VEGF-A, which appears to be a very effective treatment for wet AMD and diabetic macular edema (DME). 

Both these products will likely be game-changers in the retina therapeutic space. Kala’s recently FDA-approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term treatment of the signs and symptoms of dry eye disease, will certainly be a major player in the dry eye market in 2021.

Dr. Mali's top 5 stories in ophthalmology for 2019

3. Artificial intelligence will continue its rise and application in clinical ophthalmology

I have been writing about artificial intelligence (AI) and its great potential for years — and rightfully so. This technology is designed to improve efficiency and data analysis, which has been strategically and successfully implemented into ophthalmology and, frankly, all of medicine. 

One particular device to keep your eye on is Notal Vision’s Home Optical Coherence Tomography (OCT) System. A new platform for monitoring wet AMD patients with its pioneering patient-operated design, it is utilized to identify intraretinal and/or subretinal fluid in the central 10° of eyes diagnosed with wet AMD. 

It will allow patients to complete the test at home while the machine-learning algorithm (Notal OCT Analyzer) performs an automated analysis, which generates a report and transmits the information to a physician.

This innovation represents the symbiotic relationship between AI and telemedicine that could revolutionize the way we monitor and determine treatment intervals for patients receiving intravitreal anti-VEGF injections. The Home OCT system will inevitably be the new standard of care in wet AMD management.

4. Telemedicine platforms will still play a role in ophthalmology

Telemedicine visits and utilization spiked in 2020 due to 

 practice restrictions and temporary shutdowns. However, it really was only an acceleration of an early trend that has been gaining traction over the past several years. 

While telemedicine will never replace a physical exam (especially in ophthalmology), I believe that telemedicine can be a helpful adjunct and service that ophthalmology practices can provide to benefit patients and patients will expect to have it available as an option in certain circumstances going forward.

5. Virtual ophthalmology conference options will be present for the majority of 2021

The adaptability of ophthalmology conferences and professional organizations in 2020 has been incredible. 

I have been so impressed by organizations such as the 

 American Society of Retina Specialists (ASRS)

, which put together successful and informative virtual annual meetings in such a short amount of time has been nothing short of amazing. 

The strong leadership of these organizations should be applauded for their ability to adapt and pivot during this challenging time to deliver stellar meetings. 

Due to this success, my prediction is that the major meetings in ophthalmology in 2021 and beyond will continue to have a virtual option to allow flexibility and more widespread participation for future meetings. 

In addition, meetings that take place during the end of 2021 will likely have a hybrid model: a live in-person meeting (with limited number of registered participants) and a simultaneous virtual meeting platform for those unable to attend the live event. 

The constant exchange and flow of ideas and knowledge is the lifeblood of our profession and will continue to thrive successfully.

With 2020 behind us, 2021 is shaping up to be an amazing year. I look forward to keeping you updated throughout 2021 and beyond.


is a board-certified ophthalmologist and award-winning vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida. He is also the founder & CEO of Mali Enterprises.He can be reached at malienterprisesglobal@gmail.com. Dr. Mali’s relevant financial disclosures include Genentech/Roche (consultant, speaker), Notal Vision Inc. (consultant, speaker), Sorrento Therapeutics (Nasdaq:SRNE) equity stock shareholder, Kala Pharmaceuticals (consultant, speaker).

1. Mali, Joshua. Dr. Mali’s Top 5 Predictions in Ophthalmology for 2019. 

Articles

In light of an unprecedented year filled with technological advancements and pivots, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2021.

Dr. Mali's top 5 predictions for ophthalmology in 2021


Read Dr. Mali's article on what to expect in the new year. 

Videos

Joshua Mali, MD, speaks on his annual top 5 predictions in ophthalmology for what's to come in 2021.

Dr. Mali: Top 5 predictions for ophthalmology in 2021

It’s that time of the year again when I reflect on an exciting and dynamic year in ophthalmology! Here are my top 5 most significant stories in ophthalmology for 2019:

Dr. Mali's top 5 stories in ophthalmology for 2018

FDA approves brolucizumab for treatment of wet AMD

As of this writing, it has been more than eight years since a new anti-VEGF has been approved, and it could not have come at a better time. As the prevalence of exudative age-related macular degeneration (wet AMD) continues to climb worldwide, 

with a new FDA-approved blockbuster medication to combat wet AMD: brolucizumab (Beovu).

The approval was based on the phase III results of the HAWK and HARRIER trials. The drug met its primary endpoint of non-inferiority versus aflibercept in best-corrected visual acuity (BCVA) and exhibited superiority in key retinal outcomes at year one (48 weeks).
	Secondary endpoints at year two (96 weeks) reaffirmed superiority of brolucizumab in reduction of retinal fluid, an important marker of disease activity in wet AMD.

Additionally, of the patients on brolucizumab who successfully completed year one on a 12-week dosing interval, 82% in HAWK and 75% in HARRIER were maintained on a 12-week dosing interval in year two.

Study targets potential treatment for nAMD

In late June, AbbVie announced its plan to acquire Allergan for $63 billion in one of the 

largest purchases the financial world has seen this year

While AbbVie already had its foot in the door with its blockbuster drug adalimumab’s

(Humira) indication for non-infectious uveitis, the Allergan acquisition takes its stature to an elite level in ophthalmology. With Allergan’s staple of bread-and-butter products like onabotulinumtoxinA (Botox), cyclosporine (Restasis), and dexamethasone (Ozurdex) providing a respectable cash flow, the true jewel of the deal lies within Allergan’s potentially lucrative pipeline.

In particular, two promising retina treatments: 

) for the treatment of geographic atrophy (dry AMD) and abicipar pegol for treating wet AMD. These new treatments for retinal conditions affecting millions of patients aim to lead in both clinical and financial success.

Macular Degeneration Association unveils AMD Centers of Excellence

Founded in 2007, the Macular Degeneration Association (MDA) is a nonprofit health organization dedicated to educating and empowering AMD patients through ophthalmic education, advocacy, and fundraising efforts. A new grassroots initiative for AMD patient care was unveiled earlier this year: AMD Centers of Excellence (COE).


	
	This program designates eyecare practices that evaluate and treat AMD patients across the United States as providing them with the highest standard of care. This distinction will help patients locate these outstanding facilities in their area.

In addition, being a member of the AMD COE gives practices’ patients access to patient education materials and services. This grassroots effort is supported by the leading AMD patient advocacy organization in the country, with credentials and criteria developed to serve the best interests of AMD patients.
	
	For more information, go to 

4. Alcon’s new trifocal IOL implant granted FDA approval

Alcon’s AcrySof IQ PanOptix Trifocal IOL, the first trifocal lens for U.S. patients undergoing cataract surgery, 

.
	
	The device has been clinically shown to deliver an exceptional combination of near, intermediate, and distance vision while significantly reducing the need for glasses after surgery.


	
	As IOL technology continues to evolve and reach new heights, ophthalmologists are able to achieve advanced clinical results and increasingly deliver patient satisfaction outcomes.
	
	

Striving for perfection: Creating the perfect IOL

5). Healthcare law reform maintains status quo


	While there seemed to be some momentum earlier this year regarding potential positive reforms to existing healthcare regulations, these have taken a backseat to other legislative priorities and political issues.
	
	However, 

notable changes affecting ophthalmologists

 have included Medicare Advantage plans utilizing step therapy for Part B drugs and additional cuts by CMS for procedures like cataract surgery.

Ultimately, it will take the efforts of all Americans to solve the healthcare policy issue.

I also have some ideas on how to develop the nation’s healthcare policy for all sides-patients, physicians, hospitals, pharmaceutical companies, insurance companies, and the government.

There must be stabilization in the U.S. healthcare system to allow physicians/ophthalmologists to continue to provide the best healthcare delivery for patients.   

This has been a tremendous year in the history of ophthalmology and it provides momentum to the coveted year of the eye: 2020. I look forward to keeping you updated throughout 2020 and beyond!
	
	

 is a board-certified ophthalmologist and award-winning vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, FL.


	E: malienterprisesglobal@gmail.com
	www.malienterprises.org
	P: 941-923-2020

Dr. Mali’s relevant financial disclosures include the following: AbbVie (stock equity owner); Allergan (consultant/advisory board/investigator/research funding); Macular Degeneration Association (medical director/consultant/speaker); Novartis (consult-ant/speaker), and founder and CEO of Mali Enterprises.

1.  Novartis. Two-year data for Novartis brolucizumab reaffirm superiority versus afliber-cept in reducing retinal fluid in patients with nAMD. Available at:  https://www.novartis.com/news/media-releases/two-year-data-novartis-brolucizumab-reaffirm-superiority-versus-aflibercept-reducing-retinal-fluid-patients-namd.
	2. Mali J. Ophthalmology grabs Wall Street’s attention. 

. Available at: https://www.ophthalmologytimes.com/Blogs/WallStreet.
	3. Mali J. Macular Degeneration Association unveils AMD Centers of Excellence. 

. Available at: https://www.ophthalmologytimes.com/blogs/macular-degeneration-association-unveils-amd-centers-excellence.
	4. Alcon. Alcon introduces AcrySof IQ PanOptix TriFocal IOL in the US, the first and only FDA-approved trifocal lens. Available at: https://www.alcon.com/media-release/alcon-introduces-acrysof-iq-panoptix-trifocal-iol-us-first-and-only-fda-approved.
	5. Mali J. Dr. Mali’s Top 5 stories in Ophthalmology for 2018. 

. Avail-able at: https://www.ophthalmologytimes.com/article/dr-malis-top-5-stories-ophthalmology-2018.

Before the COVID-19 pandemic, retina specialists had limited experience with artificial intelligence (AI) and digital health care, which can include services such as telemedicine. Interactions with AI in retina were perceived as something—although feasible—best kept for future implementation. 

 was a vague term, pregnant with promise but lacking a clear use case for daily patient interactions. However, over the past 2 years, retina specialists and their patients have learned how AI may be a tool physicians can use to monitor patients for disease progression, how telemedicine might mean more than a mere video chat between patient and clinician, and how the tools of the 21st century were closer to real-world practice than anticipated.

Applications of digital health care differ from specialty to specialty, and patient expectations and appetites for digital offerings may vary based on personal experience. It behooves modern retina specialists leveraging digital health care in their clinics to ensure patients understand what the benefits and limitations of digital health care are in retina.

The increasing ubiquity of technologic platforms replacing analog mediums—from QR codes replacing printed restaurant menus to Zoom conferences in lieu of in-person meetings—has resulted in many retina patients feeling more comfortable with the concept of digital medicine. Even among our retired patients, whose lives may be less dictated by video conferencing than their working-age counterparts, the learning curve for digital interfacing has been flattened. This means that an aversion to digital medicine, one of the pre-2020 challenges faced by retina specialists who wished to implement AI-based services into their care models, has been erased.

Still, some retina patients may have unrealistic expectations about how digital health care can alleviate the burden associated with retinal diseases, such as wet age-related macular degeneration (AMD). Although the point is obvious to clinicians, I sometimes remind my patients I cannot perform a comprehensive eye examination via video conference and am unable to evaluate visual function based on subjective self-reported assessment. For some conditions, telemedicine’s limitations mean in-office examinations remain the standard for evaluation. For other conditions, digital options offer cutting-edge health care. Consider the example of a patient with dry intermediate AMD. In a more analog age, such a patient would be handed an Amsler grid and instructions to call the office if the grid’s uniform pattern became distorted, as a change might indicate a conversion from intermediate to wet AMD. This model could be prone to lack of adherence and a misunderstanding of instructions and places the burden of initiating care on the patient.

If that same intermediate AMD patient was referred to the ForeseeHome AMD Monitoring Program (Notal Vision), they would be enrolled in a modern AI-based digital health care framework. After a referring physician determines a patient with dry intermediate AMD is well suited for home monitoring, the Notal Vision Monitoring Center, which is the provider of the ForeseeHome AMD Monitoring Program, works with the patient to set up the device, teaches the patient how to perform daily preferential hyperacuity perimetry tests, and serves as a troubleshooting liaison. Patient adherence is watched by the monitoring center, and patients who are not regularly performing at-home tests are contacted by the center to ensure no hardware problems or other health care issues are interfering with consistent evaluation.

Results of routine at-home testing are sent to the Notal Vision Monitoring Center, which relies on an AI algorithm to detect aberrations in patient performance that might indicate a conversion from intermediate to wet AMD. If AI flags the patient’s test results, an in-house ophthalmologist reviews the report and pings the referring physician’s office if it is determined that the referring physician should be alerted. That office may then reach out to the patient to schedule an in-person examination to see whether conversion to wet AMD has occurred.

In this digital health care model, a patient with intermediate AMD receives routine AI-based monitoring services while outside the clinic in addition to the regularly scheduled visits they have with their provider. Retina specialists should note that a Medicare-covered home monitoring program is not a stand-in for clinical examination, but a digital supplement to in-person visits as the medium of extra care.

The real-world case of a 75-year-old woman named J.B. illustrates the value of home monitoring for wet AMD conversion. J.B. was a patient with intermediate AMD OD and wet AMD OS, which was treated with aflibercept (Eylea, Regeneron Pharmaceuticals, Inc). Visual acuity (VA) measured 20/30 OD and 20/150 OS at her most recent visit. Given that she was a high-risk patient with intermediate AMD and a history of wet AMD in the fellow eye, I referred J.B. to the Notal Vision Monitoring Center for enrollment in the ForeseeHome AMD Monitoring Program.

Six months after initiating at-home monitoring, my office received an alert that J.B.’s most recent test flagged her for possible conversion to wet AMD OD. My office scheduled an examination, at which point I found that her VA remained stable at 20/30 OD. Fundus photography revealed macular drusen and changes to the retinal pigment epithelium and did not show evidence of subretinal hemorrhage (

). Optical coherence tomography imaging revealed only borderline findings (

). Fluorescein angiography depicted a small choroidal neovascular membrane temporal to the optic disc that did not involve the central macula (

). I gave J.B. a diagnosis of wet AMD based on these findings. Initiation of aflibercept therapy resulted in stable VA of 20/25 OD.

Home-based monitoring detected asymptomatic conversion to wet AMD from intermediate AMD in J.B. while VA was at least 20/40, which is particularly good news when one considers the findings of a 2020 real-world study that found that detecting wet AMD before VA dips below 20/40 is key to maintaining 20/40 vision after 1 or 2 years of anti–VEGF therapy. In the case of J.B., detection of wet AMD might have occurred after she passed the 20/40 VA threshold if not for use of the ForeseeHome AMD Monitoring Program.

Digital health care offerings frame your practice as a cutting-edge institution that prioritizes the latest in retina care. Although some of your patients might have a different concept of what digital health care looks like, educating them on the parameters of telehealth vis-à-vis retina care will set reasonable expectations. Implementation of digital health care platforms, such as the ForeseeHome AMD Monitoring Program, allow your practice to leverage the power of AI to offer care outside of your clinic, thereby launching your practice into the future.

1. Ho AC, Kleinman DM, Lum FC, et al. Baseline visual acuity at wet AMD diagnosis predicts long-term vision outcomes: an analysis of the IRIS registry. 

2020;51(11):633-639. doi:10.3928/23258160-20201104-05

Mali is a board-certified ophthalmologist and award-winning vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida. He is also the retina medical director of the Macular Degeneration Association and the founder and CEO of Mali Enterprises (www.malienterprises.org)

Over the past 2 years, retina specialists and their patients have learned how AI may be a tool physicians can use to monitor patients for disease progression, how telemedicine might mean more than a mere video chat between patient and clinician, and how the tools of the 21st century were closer to real-world practice than anticipated.

The offerings and limitations of digital health care in ophthalmology

Joshua Mali, MD, is an ophthalmologist and vitreoretinal surgeon based in Sarasota, Florida. He also serves as retinal medical director of the Macular Degeneration Association (DMA), and is the founder and CEO of Mali Enterprises.

Welcome. My name is Dr. Joshua Mali. I'm a board-certified ophthalmologist and vitreoretinal surgeon in Sarasota, Florida. I'm also the founder and CEO of Mali Enterprises. And I serve as Retinal Medical Director of the Macular Degeneration Association [MDA]. I'm so excited to be here with you today to talk about what the faricimab approval will mean for retina specialists.

For retina specialists, this is a great time. I think this will be a revolutionary treatment for wet AMD patients. Faricimab has the ability to extend patients out to a possible 16-week dosing interval, while still maintaining robust visual gains that we see with our current anti-VEGF therapies. I think providing that combined mechanism of the Ang-2 and anti-VEGF properties really give a retina specialist an edge on treating wet AMD and getting patients the best possible outcome.

I think this will help patients that are treatment naive as well as patients that are on current therapies from 4- to 12-week interval that we've been unable to extend past those intervals. So give these patients a chance to get out to more extended intervals than there they are on current therapies.

And finally, of course, I think it will help refractory patients. I think patients that are on maximal medical therapy of our current agents will certainly benefit from faricimab approval as another treatment, another tool in our tool belt, to help treat patients with wet AMD and provide them with the best possible outcome and the best possible care that we can.

So I know that all the retina specialists in the country are super excited about this new treatment and new potential approval. I'm honored to be a part of that and help our patients achieve the best possible visual outcome. And faricimab will make that happen. Thank you very much.

Joshua Mali, MD, shares how the FDA-approved faricimab-svoa (Vabysmo, Genentech) will change the treatment landscape for wet AMD and DME.

Faricimab FDA approval: Dr. Joshua Mali shares what this new therapy will mean to retina specialists

In light of an unprecedented year filled with technological advancements and continued challenges, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2022.

1. COVID-19 and its variants will continue to dominate the headlines in 2022, but potential game-changing progress will be made in the realm of therapeutics.

It is obvious that COVID-19 and its variants will likely continue to be the dominant story into 2022. Whether it is identifying new variants, such as Omicron, or battling regional case surges, it seems this virus will continue to 

invade nearly every facet of our society. However, I am confident that 2022 will deliver game-changing therapeutics to combat this virus, specifically from an unsuspecting pharmaceutical company. In particular, I have my eye on Sorrento Therapeutics, a small biotech company, as it has rapidly developed a tremendous pipeline of promising COVID-19 antibody treatments, vaccine candidates with unique mechanism of action, and diagnostic tests that could hold the key to next generational management and potential cure of this disease.

2. Susvimo will be the biggest innovation in wet age-related macular degeneration management since 2006.

Since the approval of ranibizumab (Lucentis) in 2006, we have not had such an impressive innovation in exudative age-related macular degeneration (AMD) management and sustained drug delivery until now, with the recent FDA approval of Susvimo (formerly known as port delivery system with ranibizumab). Genentech delivers significant optimism by providing a revolutionary sustained drug delivery system to relieve patient intravitreal injection burden through unprecedented durability with the potential of 6-month in-office refills while providing robust visual gains.1 Additionally, don’t forget about faricimab, the first bispecific antibody designed for intraocular use. Faricimab can simultaneously bind and neutralize Ang2 and VEGF-A, which appears to be a very effective treatment for wet AMD and diabetic macular edema, with the potential of 16-week dosing. Genentech has been an incredibly dynamic company that has produced unique innovations that will likely be game-changers in the retina therapeutic space not only for 2022 but also for many years to come.

3. Retinal gene therapy for inherited retinal diseases will make a leap forward.

I believe 2022 will be a critical year for data readouts in ophthalmological clinical trials, especially the ocular gene therapy space, where there are several exciting therapeutic agents on the horizon. One of the biotech companies I believe will achieve tremendous success in 2022 is Applied Genetic Technologies Corporation (AGTC). Their retinal gene therapy candidates for both achromatopsia and X-linked retinitis pigmentosa are impressive and will likely yield additional positive data in 2022, eventually leading to FDA approval of their first-in-class treatments for these debilitating inherited retinal diseases. AGTC is a company to watch in 2022 and is showing it is a leader in the field of ophthalmic gene therapy.

4. Geographic atrophy will have an approved treatment in 2022.

Geographic atrophy (GA) has been the final frontier in retina medicine. Although there are currently no FDA-approved treatments for GA/dry AMD that will change in 2022, Apellis Pharmaceuticals’ FDA-submitted C3-targeted therapy, pegcetacoplan (Empaveli), has been designed to regulate excessive activation of the complement cascade, which can lead to the onset and progression of many serious diseases, including GA. Despite mixed results, with only 1 of their phase 3 clinical trials achieving their primary end point, the pooled analysis was solid, and I strongly believe the data support eventual FDA approval. Not too far behind is Iveric Bio and its C5 inhibitor, avacincaptad pegol (Zimura), which appears to be very promising, and I predict it will have extremely positive interim data in 2022 from their current clinical trial. These 2 agents will usher in a new era in the treatment of GA, giving hope and optimism to patients who desperately need it.  

5. Ophthalmic media platforms will continue to diversify and demonstrate importance.

The power of knowledge and the ability to distribute information across multiple diverse platforms cannot be understated, especially in medicine. Ophthalmology has seen an incredible evolution of media platforms, originating with a limited number of scientific journals, giving way to regular periodicals with fascinating articles about cutting-edge ophthalmic technology and practical treatments, and further supplemented more recently by online/social media channels, such as podcasts, to discuss current topics and advance the field of ophthalmology in real time. The constant exchange and flow of ideas and knowledge is the lifeblood of our profession and will continue to thrive successfully through both traditional media methods and modern modes of delivery. 2022 will likely see continued expansion of these platforms, and I am truly honored to be a part of this renaissance age in medical media as a regular author and contributor to these periodicals, serving on multiple editorial boards, being featured as the medical expert in television and films, and even hosting my own podcast, 

2022 is shaping up to be an amazing year, and I look forward to keeping you updated throughout 2022 and beyond.

Mali is a board-certified ophthalmologist and award-winning vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida. He is also the founder and CEO of Mali Enterprises. Mali’s relevant financial disclosures include the following: Genentech/Roche (consultant, speaker), Sorrento Therapeutics (Nasdaq: SRNE) equity stock shareholder, and Applied Genetic Technologies Corporation (Nasdaq: AGTC) equity stock shareholder.

In light of another unprecedented year filled with technological advancements and pivots as a result of the pandemic, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2022.